Humanetics to Present at 2024 BIO International Convention in San Diego
Humanetics Corporation, a clinical-stage specialty pharmaceutical company, is set to present its novel radioprotective drug candidate, BIO 300, at the Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA. This prominent event allows industry leaders to showcase their innovations on a global stage. Ronald J. Zenk, the CEO of Humanetics, will deliver a presentation highlighting the significant progress and potential of BIO 300 on Monday, June 3, 2024.
Overview of BIO 300
BIO 300 stands out as a pioneering medical countermeasure with dual applications in both military and medical fields. It is designed to shield normal tissues from radiation damage, setting it apart from other available drugs. The drug has garnered substantial interest, funding, and research support from the Department of Defense (DOD) due to its potential to mitigate radiation's harmful effects on warfighters and civilians in the event of a nuclear or radiological incident. Given the current global landscape, the demand for such a product has increased significantly. Humanetics is working under a DOD contract to position BIO 300 for Emergency Use Authorization, aiming to make it accessible to warfighters worldwide.
In the medical field, BIO 300 is designated to enhance outcomes for cancer patients undergoing radiotherapy, with or without concurrent chemotherapy. These patients often experience severe side effects that can diminish treatment efficacy or cause serious toxicities. BIO 300 aims to protect normal tissues, thereby improving therapeutic outcomes.
Clinical Trials and Developments
BIO 300 is currently in phase 2 clinical trials, marking a critical milestone in its development. These trials are focused on evaluating the drug's effectiveness in preventing normal tissue damage during cancer radiotherapy and reducing lung damage in patients suffering from long-term COVID-19 effects. The drug is administered as an oral liquid nanosuspension and has demonstrated promising potential in minimizing radiation damage to normal tissues without compromising the effectiveness of radiation therapy against tumors. Positive results from earlier Phase 1/2a clinical trials involving non-small cell lung cancer patients undergoing chemoradiotherapy further support the safety and efficacy of BIO 300, highlighting its promise for favorable clinical outcomes.
About Humanetics Corporation
Humanetics Corporation is an advanced clinical-stage specialty pharmaceutical company focused on developing and commercializing radioprotectant drugs. These drugs are aimed at preventing harm caused by ionizing radiation exposure, enhancing protective measures in cancer radiation therapy, and guarding against the long-term damaging effects of COVID-19.
Humanetics' presentation at the BIO International Convention is anticipated to draw significant attention from industry leaders and stakeholders, given the innovative nature and potential impact of BIO 300. This drug represents a significant advancement in radioprotective medicine, with the ability to protect individuals in both military and medical settings from the adverse effects of radiation exposure.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
